Dragon09/odtu_chatbot huggingface dataset:
quantum noise evading measurement for gravitational wave detectors

worldwide efforts are undertaken today towards improving the detection of gravitational waves gw the detection of these waves allows to deepen our understanding of the universe its composition and its creation today environmental or technical sources of noise of gw detectors are well controlled as a result the strain sensitivity of most gw detectors is fundamentally limited by quantum noise throughout most of their detection bandwidth in particular one effect called the quantum back action qba is dominant typically below 100hz while shot noise dominates at higher frequencies one common solution to beat the fundamental quantum limit is to use squeezed light but this technique is only effective within a relatively narrow frequency band for broadband detection it is necessary to impose a frequencydependent tailoring of the squeezed light source an expensive solution which requires the construction of large scale hundreds of meters fabrypero cavities in this research project we propose the experimental investigation of an alternative solution for beating both shot noise high frequency and qba low frequency simultaneously the technique relies on the macroscopic entanglement of the gw detector and an atomic spin ensemble which behaves as a negativemass oscillator by probing both systems using a nondegenerate entangled source of light it becomes possible to beat the quantum limit over a large spectral bandwidth we intend to build a compact proofofprinciple setup which would serve as a prototype for applications in existing large scale gw detection systems as well as in the upcoming einstein telescope due in 2035 we believe it is competitive with stateoftheart techniques currently implemented on gw detectors with nevertheless a great advantage in price compactness and versatility of integration if successful our project could significantly contribute to the next generation of gw detectors
advanced biomarker discovery for earlier diagnosis and improved prognosis of nafld stages via high resolution mass spectrometry

nonalcoholic fatty liver disease nafld has a global prevalence of nearly 25 ie affects one quarter of the adult population early phase nafld is reversible and can be treated but it may progress towards lifethreatening stages such as nonalcoholic steatohepatitis nash cirrhosis and hepatocellular carcinoma hcc the conventional diagnosis of nafld stages requires liver biopsy and is timeconsuming and costly and there is an urgent need to identify biomarkers that can be applied in routine clinical settings such as through bloodbased testing the identification of blood biomarkers would support earlier diagnosis and improved assessment of prognosis ultimately supporting preventiveintervention measures to avoid progression to late stage liver disease and thus saving lives in renaissance a stateoftheart liquid chromatographyhigh resolution mass spectrometry lchrms metabolomics screening will be conducted upon the blood and bloodderived exosomes of a unique deeply phenotyped cohort of nafld patients for molecular biomarker discovery notably exosome analysis shows promise for the identification of novel disease signatures but has yet to be applied to characterize nafld providing high potential for the identification of new diagnosticprognostic biomarkers for nafld furthermore the lchrms screen will be supported via targeted assays of redox metabolites and protein markers of acute inflammation the integration of nontarget and target data will provide insight into the underlying mechanisms of disease progression and further knowledge about potential causative factors of nafld
making augmedit lumi standard in neurosurgical surgery in 3d guidance 3d

augmedit develops and brings to market augmented reality saas applications for surgeons ar gives the possibility of viewing holographic images in 360 it is our mission to transform the complete 2d clinical practice into an intuitive 3d world as the first company in the world until now ar applications are unavailable in neurosurgical setting due to lacking accuracy and automatization of workflows augmedits lumi elite solves this problem we make surgery safer by guiding the medical specialist with an intuitive ar application that automatically generates holograms from medical imaging and projects them with a surgical plan on the patient this holographic experience improves the insight of surgeons and drives massive cost savings for medical institutions crucially lumi elite will improve the preoperative and operative care of the patients 1 hologram is worth more than a 1000 scans
sustainable deep tech innovation for aquatic oil spills cleanup

inobiostar is an earlystage startup leaded by ceo and founder dr tatjana paulauskiene the company was founded in 2020 as a spinoff company of klaipeda university with the aim to create and develop deep tech innovations towards clean seas inobiostar was excited to participated in techhub startups preaccelerator tprogram in 2021 where the idea of innoaerogel became top5 at techhub demo day we were selected to be a part of baltics slovakia climaccelerator 2021 accelerator for climatepositive startups supported by climatekic inobiostar together with the strategic partner klaipeda university in 20212022 implemented the product commercialisation project inobiotech baltija development of a biotechnological treatment method for oil spills in the baltic seainobiostar is currently in the process of receiving de minimis grant from klaipeda science and technology park inospurtas and lithuanian innovation centre interinolt for consultancy servicesour new brand product is innoaerogel sustainable highly efficient biodegradable and reusable waste paper based material sorbent for aquatic oil spills cleanup the idea is patented in state patent bureau of the republic of lithuania and is being patented in european patent office the problem which we are solving have never been so actual for the human with arising awareness on climate change and health we see our mission to contribute significantly to the efforts of modern society to save the futurethe objective of this project is to develop innoaerogel innovation from early stage and noninvestment ready to modern knowledgedriven resourceefficient and competitive product on the global market leaded by woman during the project implementation we are planning to perform 3 main tasks to prepare for fundraising and eic accelerator to find key innovation partners and encourage more women to join blue biotech sector
uncovering the missing x factors to understand sex bias in cardiovascular disease

cardiovascular diseases cvd occur and progress differently in men and women and the risk dramatically increases with age hormone differences have been suggested to account for the sex difference by observing that younger women are regularly protected from cvd until postmenopause however hormone replacement therapies failed to provide cardioprotection suggesting that other biological factors contribute to sex disparities in cvd development other likely contributors to sex bias are genes that escape female x chromosome inactivation an understudied epigenetic phenomenon that has so far not been linked to sex differences in cvd these socalled escaper genes have twice the gene dose in females compared to males and thus are likely to contribute to sexbased differences escapex aims to identify sexspecific protective mechanisms by disentangling the impact of hormones and sex chromosomes on sex bias in cvd first we will combine the transgenic fcg mouse model in which the sex chromosome complement xx or xy is independent of the gonadal hormones with the pressure overload heart failure model which shows a sexspecific phenotype next escapex uses our established escaper detection pipeline to map and characterize escaping during cardiac aging and disease the resulting dataset will uncover the escaper gene function the extend of lineagespecific escaping and how the escaper landscape changes during aging and disease building on those findings escapex aims to overexpress the identified escapers in the disease model using viral vectors with the ambitious goal to rescue the sexspecific phenotype finally we will combine allelespecific genomics and singlecell technology to explore if xreactivation occurs in cardiac aging and disease and if such a novel disease mechanism further contributes to sex differences escapex will elucidate new regulatory disease mechanisms and relevant therapeutic candidates forming the basis of new sexspecific therapies
automated synthesis of algal polysaccharides

through photosynthesis marine algae convert gigatonnes of carbon dioxide into carbohydrates every year in the form of algal polysaccharides these structurally complex biomolecules determine to a large extent how much carbon is stored in the oceans specialised marine bacteria unlock this carbon energy by breaking down the polysaccharides through the action of carbohydrateactive enzymes cazymes and releasing the carbon dioxide back into the atmosphere however some of the polysaccharides are not recycled quickly but sink into the deep sea and sediments where they can store carbon for millennia to better understand these processes great efforts are needed to further explore the marine carbon cycle the same advances are also important to support emerging efforts to use algal biomass as a new sustainable resource for the bioeconomythe enzymatic machinery responsible for the degradation of polysaccharides by marine bacteria has remained largely unexplored because of the size and heterogeneity of algal polysaccharides pure and defined oligosaccharides needed for systematic screenings of marine cazymes are currently not available since conventional chemical synthesis is timeconsuming and often not general enough asap aims to obtain collections of oligosaccharides related to different classes of algal polysaccharides by using automated glycan assembly aga technology oligosaccharides with many different sequences and sulfation patterns will be prepared from small sets of monosaccharide building blocks incubation of the synthetic oligosaccharides with samples containing carbohydratedegrading activity and subsequent hplcms analysis of the degradation products will provide information on 1 the collective enzyme activities of a bacterial community in seawater and sediment samples 2 the abilities of individual bacterial strains to degrade specific polysaccharides 3 the substrate specificities of purified cazymes
application of metalorganic frameworks synthesized by microfluidics in microextraction for metabolomics development of a noninvasive bioanalytical method for early diagnosis of fatty liver diseases

nonalcoholic fatty liver disease nafld is the most common liver disorder worldwide which affects to around 25 of the population it is associated with obesity and diabetes and may lead to chronical liver diseases and cancer its diagnosis and prognosis involve a liver biopsy that entails certain unavoidable risks and errors and present a high cost the determination of biomarkers in biological fluids particularly metabolomics is one of the most promising tools as an alternative to these more conventional invasive procedures thus it is important to develop a platform to monitor and diagnose the disease in a wider population as well as to track the disease evolution the aim of m4liver project is to design and fabricate an effective microextraction device for the development of a simple and noninvasive bioanalytical method suitable for the early diagnosis prognosis and monitoring of fatty liver diseases the method is based on the identification and quantification of biomarkers in plasma samples they will be extracted and preconcentrated using a small device coated with a hybrid material with antifouling properties which is composed of a metalorganic framework mof and a polymeric phase with the aim of ensuring scalability and reproducibility the mof particles will be prepared using microfluidics overall the combination of the preconcentration technique the impressive mof sorption capacity and polymer stability in this analytical method will contribute to gain insight into the role of biomarkers in nafld moreover given the simplicity and the possibility of carrying out parallel and fully automatic analysis with this approach its implementation in routine clinical laboratories as a simple and economical platform is feasible
improving quality and patient safety in surgical care through standardisation and harmonisation of perioperative care in europe

adverse events in health care are suffered by between 8 and 12 of patients admitted to hospitals in the eu and are accountable for around eur 21 billion in direct costs surgical adverse events are one of the most common types reported the safest project aims at improving and harmonising perioperative patient safety by establishing widely supported perioperative patientcentred eu standardised practices to address this challenge safest goes beyond state of the art in surgical patient safety by addressing the whole perioperative patients pathway beyond the hospital care thus ensuring the continuum of care patients will participate as coequal partners throughout the project their engagement will start with the broad european consensus jointly with other key stakeholders to design the safest standardised practices for perioperative care the safest standardised practices will be implemented in 10 hospitals from 5 eu countries through a perioperative quality improvement learning collaborative pqilc our evaluation of the implementation both from a process and a results perspective will allow assessing the impact of the implementation of standardised practices on the improvement of clinical outcomes and to identify contextual facilitators and barriers at micro meso and macro levels providing new evidence to translate standardised evidencebased guidelines to clinical practice the uptake of the safest standardised practices will be taken a step further by inviting 100 hospitals across eu27 associated countries and beyond to selfevaluate and create an international benchmarking assessmentfurthermore we will ensure that safest makes an impact beyond its lifespan with ambitious dissemination and exploitation plans that include launching an openaccess benchmarking platform for european hospitals and constituting an international network on perioperative patient care
therapeutic epigenetic enhancement of the innate immunity to effectively combat antimicrobial resistance inarmor

antimicrobial resistance amr multidrug resistance whereby pathogens evolve to resist antibiotic drugs is designated by who one of the top 10 health threats of our time and is a top 3 priority health threat requiring eu level coordination amr was estimated to be linked to 495 million deaths in 2019 the next global pandemic could be a multidrug resistant bacterium or emergence of pandrug resistant strains resistant to all existing drugs alternative therapeutic approaches are proving to be expensive and slow to develop whilst also facing the risk of evolving strains the innate immunity presents the strongest potential to tackle amr as it can generate antimicrobial molecules and proteins that directly inhibit microbial survival inducing such proteins has shown effective antimicrobial activity against bacteria viruses fungi protozoa building on this approach leading professors and researchers from 9 universities and research institutes are collaborating with 7 medical and industry partners representing 9 eu countries to introduce a novel class of immune system inducers able to enhance the bodys own innate microbial defence mechanisms to combat amr and reduce incidence of the 13 listed most dangerous infections including 2 of the top 3 priority1 infectionsinarmor will optimise an already developed drug platform using computer aided drug design and insilico approaches in tandem with a nanotechbased drug delivery system for the first target indication the developed therapy will be preclinically validated for safety and efficacy invitro and in vivo to complete all investigational medicinal product requirementsupon completion inarmor will be prepared for clinical validation upon commercialisation inamor could potentially save more 4mn lives worldwide and result in the significant burden reduction of antibiotic development with longterm cost reduction impact of 107bn whilst reducing the global disease burden by 9684mn dal
the mother within uterus politics and technology as lived experience lifemother

at the frontier of research in assistive reproduction technologies arts and organ transplantation motherhood is being reconceived uterus transplantation utx pioneered in sweden in 2014 and now in clinical trials in 16 countries including the united states us is among the newest experimental arts for people pursuing gestational and genetic motherhood as utx moves across borders into different sociopolitical conceptions and contentions of gender reproduction and motherhood it becomes a prism for exploring the stakes practices and meaning attributed to gender and reproductive rights in different societies ultimately this technoscientific frontier is relevant to everyone representing the pursuit of not only reproduction but also of a particular form of gendered embodiment by way of a thoroughly gendered organ lifemother examines how the technological pursuit of mothering life via utx moves across borders and into different healthcare systems and lifeworlds opening to other arrangements of gender the body motherhood and reproductive rights the overall aim of lifemother is to develop a personcentered theoretical framework for understanding the interplay of three elements 1 frontier technoscience 2 cultural politics of the body reproduction and gender and 3 lived phenomenological experience this aim embeds methodological contributions for studying the social impacts of frontier experimental science i ground this framework in an interdisciplinary comparative ethnographic study of clinical and domestic home sites of four utx clinical trials in the us and sweden tracing the technological development alongside its lived experience by studying the practices and discourses of healthcare practitioners advocacy groups patients donors and families i supplement this with archival research to map compare and contextualize shifting cultural politics surrounding the uterus reproduction gender and the body in the us and sweden
markov chain monte carlo using couplings toward scalable statistical inference

this project develops a statistical toolbox for the approximation of probability distributions that commonly arise in data analysis the problem of approximating probabilities arise in many tasks of data science in bayesian statistics and its many variants in classical hypothesis testing with pvalues in likelihoodbased methods when the model involves latent variables in models with intractable likelihoods in the construction of knockoffs for principled variable selection for example stateoftheart methods for such approximations include markov chain monte carlo mcmc where a markov chain is generated in such a way that it converges to the probability of interest as the length of the sequence goes to infinity this stands at odds with modern developments in computing hardware which provide an increasing number of parallel processors but where each process has a stagnating clock speed methods that are amenable to parallel computing must emerge to help scientists in all fields to make the most of their data the project builds upon a framework called unbiased markov chain monte carlo umcmc in which accuracy improves arbitrarily with the number of parallel runs each run involves the generation of coupled markov chains for a random time horizonpart 1 develops umcmc to realize its potential as a comprehensive basis for probabilistic computation on modern hardware the project includes theoretical analyses of cost and measures of efficiency and methodological innovations towards adaptive efficient robust and convenient computationpart 2 contributes to the applicability of umcmc by conceptualizing the design of coupled markov transitions and considering a number of challenging settings distributions supported on submanifolds and their application in economics distributions on graphs and their applications in the fight against malaria and bayesian nonparametric models for cell type deconvolution from transcriptomics data
nature3b including nature in decision making of central banks investment benchmarks bond issuers

nature3b aims to make a significant contribution by developing i natureprotecting benchmarks for investors such as pension funds or insurance akin to eu parisaligned benchmarks eu pabs ii a natureprotecting bond framework particularly targeted at municipalities and corporates and i six tools for central banks esas ncas see outcomes 16 in the consortium overview below as a consortium including three current members of the eus platform on sustainable finance including the head of its data science hub and lead author of eu pabs nature3b is uniquely positioned to achieve real world impact following the success of eu pabs which grew beyond 100 billion in assets within less than 3 years european commission 2023 the consortium expects that natureprotecting benchmarks can exceed 10bn within three years after the launch given the fortunate timing of the eu green bond standard applying from december 21st 2024 and the 60 corporate and municipality supporters already interested in the concept of natureprotecting bonds the consortium expects an issuance volume of 30bn within 3 years of launch these could for instance fund marine ecosystem protection of gozo malta support the pape nature reserve of liepaja latvia or encourage forest restoration near sanok in southeast poland with considerable work experience with central banks esas and ncas nature3b is confident that 15 of them will use a relevant tool following the project the tools include 1 nature dependency dashboard 2 asset level risk database 3 naturerelated scenarios portal 4 naturerelated stress test models 5 portfolio financial system nature alignment tool 6 natural language processing nlp tools for sfrd biodiversity impact analysis and tnfd scoring
deorbiting and collision avoidance technologies for scalable sustainable space access

aurora propulsion tech supplies satellite manufacturers with reliable solutions for propulsion attitude orbit control collision avoidance endoflife deorbiting we aim to enable effective satellite 1500 kg missions ensuring that they are carried out safely in low earth orbit regions and dont result in space debrisin this eic accelerator project we focus on the industrialization of aurora plasma brake apba novel patented zero propellant microtetherbased solution for quick safe deorbiting of smallsats apb can be complemented by our existing products such as waterbased resistojet thrusters arm to simplify deployment arm derivatives to provide collision avoidance capabilitiesour technology is designed for costeffective largescale production to meet the demands of the growing new space industry with 3500 satellites to be launched in 2027 remove the barriers for new entrants it is also aligned with the upcoming new regulation on sustainable space use